Shows
WTR Healthcare SpotlightAinos' Director of Corporate Development Jack Lu on Why SmellTech Platform AI Nose is a Foundational Product in AIIn our latest WTR Healthcare Spotlight podcast, we were joined by Jack Lu, Director of corporate Development at Ainos (NASDAQ: AIMD) to discuss the company's pioneering smell digitization AI technology platform, AI Nose; diversification of the platform's penetration across multiple verticals through strategic partnerships; commercialization opportunities and expansion goals.2025-07-2223 minWTR Healthcare SpotlightLisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic CancerIn this episode of WTR Healthcare Spotlight podcast, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties. We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones. 2025-07-1823 minWTR Healthcare SpotlightCybin CEO Doug Drysdale On What Distinguishes CYB003 from Other Aspiring Novel Depression TreatmentsIn our first rebranded WTR Healthcare Spotlight, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscapeCybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are ps...2025-07-1421 minWTR Healthcare SpotlightA Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech LandscapeIn this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh, Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF),and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of biotech industry folk: The implications of the Trump Administration's FDA reforms and AI's role in reshaping the industry.With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kady...2025-06-2524 minWTR Healthcare SpotlightTrevi Therapeutics CEO Jennifer Good Discusses Oral Haduvio Benefit in Chronic CoughTrevi Therapeutics CEO Jennifer Good joins us on this week’s WTR Biotech Spotlight to talk about the recent and impressive clinical data for Haduvio in IPF-associated chronic cough and refractory chronic cough. We discuss Haduvio’s unique mechanism and unscheduled status, supported by a human abuse study. Listen to learn more about Trevi Therapeutics and how Haduvio could change the chronic cough treatment landscape.2025-06-1829 minWTR Healthcare SpotlightHow the Biomarker Era Will Transform the CNS Treatment Landscape with Psilera CEO Dr. Chris WitowskiIn this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and t...2025-06-1214 minWTR Healthcare SpotlightApimeds Pharmaceuticals CEO Erik Emerson Discusses Purified Bee Venom for Knee Osteoarthritis and Other Inflammatory ConditionsOn this week’s WTR Biotech Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.2025-06-1129 minWTR Healthcare SpotlightZomedica's (OTCQB: ZOMDF) CEO Highlights Its Innovative Product Offerings and Significant Growth Opportunities in the Animal Healthcare MarketCEO of Zomedica (OTCQB: ZOMDF) Larry Heaton joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Small-Cap Spotlight episode. Since 2021 Zomedica has expanded its suite of innovative offerings from one product to six. All are proprietary, highly differentiated either diagnostic or therapeutic devices, to help veterinarians not only improve the quality of care for pets, but also importantly to help improve the efficiency of how vets themselves operate to maximize the profitability of their practices. Heaton provides a concise overview of Zomedica’s products, explains how they differentiate themselves from what exists in the market today and the...2025-05-2817 minWTR Healthcare SpotlightEnlivex Therapeutics CEO Oren Hershkovitz, PhD Discusses Allocetra Cell Therapy and Recent Knee Osteoarthritis DataEnlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on this week’s WTR Biotech Spotlight to talk about how the company’s cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform. 2025-05-2127 minWTR Healthcare SpotlightMost-Favored-Nation Drug Pricing Lacks Executive PlanTim Gerdeman and Do Kim discuss President Trump’s executive order on lowering drug prices through Most-Favored-Nation reference pricing. They talk about the goal of the executive order and whether the government has the authority for price-setting in the pharmaceutical industry. 2025-05-1409 minWTR Healthcare SpotlightCurrent State of Biotech, Market Pressure Points, Obesity and PD-1/VEGFTim Gerdeman and Do Kim discuss the current state of biotech, what brought us here, and how the rest of year may look for the group. They also review recent market-shaping events in the obesity space and progress of the Keytruda-busting PD-1/VEGF bispecifics. 2025-05-0818 minWTR Healthcare SpotlightWTR Biotech Flashcast: Neuroscience, Alzheimer’s and Biogen IOCOn this week's episode of WTR Biotech Spotlight, Tim Gerdeman and Robert Sassoon sit down for a quick flashcast to review Robert's last three reports; Neuroscience, Alzheimer’s and Biogen IOC.2025-04-2416 minWTR Healthcare SpotlightAnnovis Bio's CEO Discusses the promise of Buntanetap in Redefining the Treatment of Alzheimer's and Parkinson's and Next StepsFounding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.2025-03-1918 minWTR Healthcare SpotlightVeru, Inc. CEO Mitch Steiner Discusses Recent Enobosarm Data and Preserving Muscle While on GLP-1 Obesity DrugsCEO Mitch Steiner joins us on this week’s WTR Biotech Spotlight to talk about the next generation of drugs focusing on lean mass (muscle) preservation for obesity patients on the popular GLP-1 therapies. He reviews the recent enobosarm Phase 2b data and highlights the importance of functional clinical benefit in addition to maintaining lean mass. Listen to learn more about Veru and its obesity drug enobosarm2025-02-2634 minWTR Healthcare SpotlightOS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next StepsCEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.2025-02-1225 minWTR Healthcare SpotlightLaunch of WTR Biotech Spotlight Podcast with Tim Gerdeman and Do KimWe are launching a WTR Spotlight podcast focused on biotech companies and industry. Listen to Tim Gerdeman, Vice Chair & Co-Founder and Chief Marketing Officer of Water Tower Research, and Do Kim, Senior Research Analyst, discuss what to expect and who will be joining us in future episodes. 2025-02-0306 min